Beyond the Cliff: How Generic Drug Makers Can Forge Value and Market Exclusivity with the 505(b)(2) Pathway
In the relentless world of pharmaceuticals, the generic drug industry stands as a titan of volume and a cornerstone of […]
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation
In the relentless and high-stakes world of pharmaceutical development, the path from molecule to market is fraught with peril. On
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
Comprehensive Guide to Pharmaceutical Portfolio Management: Essential Reading Resources
The pharmaceutical industry faces unique challenges in developing and managing product portfolios. With development timelines stretching across years or even
Comprehensive Guide to Pharmaceutical Portfolio Management: Essential Reading Resources Read Post »
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection
I. Executive Summary Follow-on pharmaceutical innovations represent a critical, often underestimated, dimension of medical progress. These advancements, which build upon
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection Read Post »
Indian Pharmaceutical Patent Prosecution: The Evolving Role of Section 3(d)
Introduction: Section 3(d) – India’s Great Patent Gatekeeper In the intricate and high-stakes world of global pharmaceutical intellectual property, few
Indian Pharmaceutical Patent Prosecution: The Evolving Role of Section 3(d) Read Post »
Navigating the Two Titans: A Comparative Analysis of the U.S. and Chinese Patent Systems for the Global Innovator
Executive Summary The global intellectual property landscape is increasingly defined by the strategic interplay and fundamental divergences between the patent
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The life sciences industry operates under a unique intellectual property (IP) paradigm where the nominal period of protection granted by
The Pharmaceutical Pricing Puzzle: How do Manufacturer Net Prices Compare with Other Common US Price References?
Executive Summary The United States pharmaceutical market is characterized by a complex and often opaque pricing structure, leading to a
Addressing the challenge of high-priced prescription drugs in the era of precision medicine
1. Introduction: The Confluence of Cost and Customization in Modern Medicine The pharmaceutical landscape stands at a pivotal juncture, characterized
